Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

#How Has The Intravenous Iron Drugs Market Growth Evolved From 2024 To 2025, And What’s Ahead?#_x000D_

The market size for intravenous iron drugs has seen a swift increase in recent years. There will be growth from $3.44 billion in 2024 to $3.81 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 10.6%. Factors contributing to this growth in the past years include an increase in iron deficiency anemia cases, escalation in chronic diseases, a rise in healthcare expenditures, an aging population, and a greater incidence of the diseases they aim to treat._x000D_

_x000D_

The market size for intravenous iron medications is anticipated to witness rapid expansion in the coming years. The market is projected to reach $5.73 billion by 2029, growing at a compound annual growth rate (CAGR) of 10.8%. The forecasted growth can be linked to governmental actions, advancements in research and development within the IV iron drug sector, heightened demand for intravenous iron treatments, an uptick in R&D activities, as well as enhancements in the formulation and administration. The anticipated trends in the forecast period include innovative intravenous iron therapies, progress in drug development, a shift in preference for more user-friendly iv iron therapies, deliberate collaborations, partnerships and procurements, and breakthroughs in novel drug delivery systems._x000D_

_x000D_

#Download a free sample to assess the report’s scope and structure:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=23430&type=smp_x000D_

_x000D_

#What Are the Primary Drivers Supporting the Market Growth of the Intravenous Iron Drugs Market?#_x000D_

The escalating prevalence of chronic kidney disease (CKD), marked by the slow and progressive decline in kidney function, is anticipated to spur the expansion of the intravenous iron drugs market. Rising instances of conditions such as diabetes and hypertension, which progressively harm the kidneys over time, are largely responsible for the spike in CKD rates. Intravenous iron medicines play a critical role in managing CKD by replenishing depleted iron resources, rectifying anemia, and elevating hemoglobin concentrations, thereby upgrading oxygen transport while simultaneously diminishing the necessity for erythropoiesis-stimulating agents. Notably, a rise of 4.2% in 2021 and 6.2% in 2022 was reported in CKD mortality rates by the Australian Institute of Health and Welfare, a government agency in Australia, in June 2024. Approximately 22,000 deaths in Australia were attributable to CKD in 2022, constituting around 11% of total mortality. As such, the escalating prevalence of chronic kidney disease (CKD) is propelling the growth trajectory of the intravenous iron drugs market._x000D_

_x000D_

#Which Primary Segments of the Intravenous Iron Drugs Market Are Driving Growth and Industry Transformations?#_x000D_

The intravenous iron drugs market covered in this report is segmented – _x000D_

_x000D_

1) By Product Type: Iron Dextran, Iron Sucrose, Ferric Carboxymaltose, Other Product Types_x000D_

2) By Indication: Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer, Other Diseases_x000D_

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy_x000D_

_x000D_

Subsegments:_x000D_

1) By Iron Dextran: Low Molecular Weight Iron Dextran, High Molecular Weight Iron Dextran _x000D_

2) By Iron Sucrose: Standard Iron Sucrose Injection, Iron Sucrose Complex _x000D_

3) By Ferric Carboxymaltose: Single-Dose Ferric Carboxymaltose, Multiple-Dose Ferric Carboxymaltose _x000D_

4) By Other Product Types: Ferumoxytol, Ferric Derisomaltose, Sodium Ferric Gluconate_x000D_

_x000D_

#Request customized data on this market:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=23430&type=smp_x000D_

_x000D_

#Which Regions Are Key Players in the Growth of the #What Are the Primary Drivers Supporting the Market Growth of the Intravenous Iron Drugs Market?# Market?#_x000D_

North America was the largest region in the intravenous iron drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the intravenous iron drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#What Are the Most Significant Market Trends in the Intravenous Iron Drugs Market?#_x000D_

Firms leading the intravenous iron drug market are placing emphasis on creating novel treatments, including intravenous (IV) iron replacement therapy, to boost safety, performance, and patient results. Intravenous (IV) iron replacement therapy is a clinical process that introduces iron into the bloodstream through an IV infusion, targeting iron inadequacy and anemia, primarily in patients who can’t properly absorb or can’t endure oral iron supplements. In June 2023, for instance, the U.S. Food and Drug Administration (FDA) agreed to the use of Injectafer, a ferric carboxymaltose injection produced by the Japan-based pharmaceutical firm Daiichi Sankyo Company Limited, known for its innovative drug development and healthcare services. This was aimed at treating iron deficiency in adult heart failure patients who fall under the New York Heart Association class II/III, with the goal of improving their exercise capacities. Injectafer has received wide acclaim as an intravenous iron therapy for quickly restoring iron levels in patients unresponsive to or unable to tolerate oral iron supplements._x000D_

_x000D_

#View the full report here:#_x000D_

https://www.thebusinessresearchcompany.com/report/intravenous-iron-drugs-global-market-report_x000D_

_x000D_

#What Parameters Are Used to Define the Intravenous Iron Drugs Market?#_x000D_

Intravenous iron drugs are iron formulations administered directly into the bloodstream to treat iron deficiency and iron deficiency anemia, especially in patients who cannot tolerate or do not respond adequately to oral iron supplements. These drugs work by rapidly increasing iron levels, facilitating hemoglobin production, and improving oxygen transport, alleviating symptoms such as fatigue and weakness._x000D_

_x000D_

#Purchase the full report and get a swift delivery:#_x000D_

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=23430_x000D_

_x000D_

#About The Business Research Company:#_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 310-496-7795_x000D_

Europe +44 7882 955267_x000D_

Asia & Others +44 7882 955267 & +91 8897263534_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model